Erdafitinib for the treatment of patients with unresectable or metastatic urothelial cancer with an FGFR3 alteration after a PD-1 or PD-L1 inhibitor

12 May 2025 - Erdafitinib is recommended as an option for the treatment of adults with unresectable or metastatic urothelial cancer ...

Read more →

Adagrasib for previously treated patients with advanced KRAS G12C mutation positive non-small-cell lung cancer

9 May 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Osimertinib mesylate in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy for patients with advanced EGFR mutation positive non-small-cell lung cancer (final guidance)

8 May 2025 - Osimertinib mesylate, when used in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy, is recommended as an ...

Read more →

Brentuximab vedotin in combination with chemotherapy for the treatment of patients with stage 3 or 4 CD30 positive Hodgkin lymphoma

7 May 2025 - Brentuximab vedotin, when used in combination with doxorubicin hydrochloride, dacarbazine and vinblastine sulphate is recommended as an ...

Read more →

Omaveloxolone for the treatment of patients with Friedreich’s ataxia

6 May 2025 - NICE is unable to make a recommendation on the use of omaveloxolone (Skyclarys) for the treatment of ...

Read more →

Up to 1,000 women a year could benefit from new at-home treatment for endometriosis

1 May 2025 - Our final draft guidance recommends linzagolix (Yselty, Theramex) with hormonal add-back therapy for adults of reproductive age ...

Read more →

Dupilumab for the treatment of patients with moderate to severe chronic obstructive pulmonary disease

24 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms

22 April 2025 - Real-world evidence is increasingly used and accepted by health technology assessment (HTA) bodies as supportive evidence ...

Read more →

Thousands of people a year could benefit from new twice a day tablet for advanced breast cancer

11 April 2025 - We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately ...

Read more →

Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment

10 April 2025 - Today, for the first time, we have given the green light to a targeted treatment for the ...

Read more →

Lorlatinib for the treatment of patients with advanced ALK positive non-small-cell lung cancer (review of TA909)

9 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Real-world evidence to support health technology assessment and payer decision making: is it now or never?

31 March 2025 - The aim of this policy article is twofold: (i) to provide a summary and update of recent ...

Read more →

Efanesoctocog alfa for the treatment and prevention of bleeding episodes in patients with haemophilia A (final guidance)

2 April 2025 - NICE has published final evidence-based recommendations on the use of efanesoctocog alfa (Altuvoct) for the treatment ...

Read more →

Pembrolizumab in combination with carboplatin and paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer

24 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Nemolizumab for the treatment of patients with moderate to severe atopic dermatitis

27 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →